Clinical Scorecard: Biodistribution of AGuIX Theranostic Nanoparticles Assessed by Magnetic Resonance Imaging in the NANORAD 2 Clinical Trial for Brain Metastases

At a Glance

Key Highlights

• AGuIX nanoparticles (~5 nm) combine radiosensitizing and MRI imaging properties enabling theranostic application.
• NANORAD2 phase II trial evaluates WBRT with or without AGuIX in patients with multiple brain metastases to improve therapeutic ratio and limit neurocognitive toxicity.
• Quantitative MRI using T1-weighted sequences allows assessment of AGuIX biodistribution, kinetics, and potential accumulation in brain metastases and surrounding tissues.

Guideline-Based Recommendations

Diagnosis

• Use baseline MRI without contrast within 2 weeks before treatment to characterize brain metastases.
• Perform T1-weighted MRI sequences post-AGuIX injection to assess nanoparticle biodistribution and tumor uptake.

Management

• Administer AGuIX intravenously at 100 mg/kg in three weekly injections timed before WBRT fractions.
• Combine AGuIX with WBRT (30 Gy in 10 fractions over 2 weeks) to enhance radiosensitization of brain metastases.

Monitoring & Follow-up

• Conduct MRI at 1 hour post-first injection to evaluate initial biodistribution.
• Perform additional MRI at 4 hours post-first injection to assess early clearance kinetics.
• Repeat MRI at 1 hour post-third injection to evaluate potential nanoparticle accumulation after repeated dosing.

Risks

• Monitor for off-target nanoparticle retention, especially in organs adjacent to irradiated brain volume, to limit adverse effects.
• Consider neurocognitive toxicity risks associated with large irradiated brain volumes during WBRT.

Patient & Prescribing Data

Patients with multiple brain metastases undergoing WBRT

AGuIX administered intravenously at 100 mg/kg in three weekly doses combined with WBRT; timing of injections optimized to precede radiotherapy fractions by 3–5 hours to maximize radiosensitization and imaging capability.

Clinical Best Practices

• Schedule AGuIX injections 2–7 days before WBRT start and before first and sixth WBRT fractions for optimal radiosensitization.
• Use quantitative T1-weighted MRI to monitor nanoparticle distribution and clearance to inform treatment planning.
• Consider patient heterogeneity and tumor burden when interpreting biodistribution and planning radiotherapy.

References

• NANORAD2 Clinical Trial Registration